Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StrateGIST J: Velzatinib in metastatic/unresectable GIST after multiple prior TKIs
jRCT2071260077Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IDRX-42 in gastrointestinal stromal tumor (GIST), sponsored by GSK. Primary endpoint: Confirmed objective response rate (ORR). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
IDRX-42
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on jRCT2071260077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260077.